Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Molecular Cancer Therapeutics|April 10, 2014
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effectSven Golfier, Charlotte Kopitz, Antje Kahnert, et al.
Molecular Cancer Therapeutics|June 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic TherapiesSabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive CancersUrs B Hagemann, Christine Ellingsen, Joachim Schuhmacher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 13, 2012
(4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studiesSora Baek, Andre Mueller, Young-Suk Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancerSora Baek, Chang-Min Choi, Sei Hyun Ahn, et al.
Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Journal for Immunotherapy of Cancer|October 7, 2021
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapyPascale Lejeune, Véronique Cruciani, Axel Berg-Larsen, et al.
Cancer Research|August 21, 2016
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid TumorsAnette Sommer, Charlotte Kopitz, Christoph A Schatz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate CancerChristoph A Schatz, Sabine Zitzmann-Kolbe, Ingrid Moen, et al.
Journal of Medicinal Chemistry|August 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha TherapiesMarkus Berger, Lars Wortmann, Philipp Buchgraber, et al.
Pageof 2